Overview

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

Status:
Terminated

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

To determine if aclerastide (DSC127) is effective in increasing incidence of complete wound closure up to 10 weeks confirmed 2 weeks later, compared with vehicle (gel without active ingredient) and compared with a standard-of-care gel, in subjects with diabetes mellitus (DM) who have chronic Wagner Grade 1 or 2 diabetic foot ulcers, 0.75 - 6cm2 in size.

Phase:

Phase 3

Details

Lead Sponsor:

Derma Sciences, Inc.
Integra LifeSciences Corporation

Collaborator:

Integrium